Navigation Links
Prometheus Licenses COLAL-PRED(R) From Alizyme
Date:11/29/2007

rometheuslabs.com.

About Alizyme plc

Alizyme is a specialty biopharmaceutical development company, focused on the therapeutic areas of metabolic disorders, gastrointestinal disorders and cancer supportive care. In addition to COLAL-PRED, it is developing cetilistat for the treatment and management of obesity and related diseases, such as Type II diabetes, renzapride for the treatment of irritable bowel syndrome ("IBS"), and ATL-104 for mucositis, a side effect of cancer therapy.

COLAL-PRED is the combination of Alizyme's proprietary colonic drug delivery system, COLAL, and prednisolone metasulfobenzoate sodium ("PMSBS"), an approved steroid in Europe. COLAL-PRED has a starch coating that is only broken down in the gut by bacteria occurring in the colon. This leads to topical delivery of PMSBS to the colon rather than systemic delivery with the objective of providing efficacy, but without the side effects of steroids; however, the efficacy and safety of COLAL-PRED must be shown in well-controlled, prospective clinical trials and approved by the FDA.

COLAL is a drug delivery technology which enables drugs to be taken orally, but then be specifically released in the colon. Achieving colonic release with conventional oral dosage forms has proven difficult because of the variation between individuals in transit times and conditions within the gastrointestinal tract. COLAL overcomes this difficulty by covering small pellets containing the drug with a coating of ethylcellulose and a specific form of amylose (derived from starch). This coating prevents drug release in the stomach and small intestine. When the pellets reach the colon, the amylose in the coating is broken down by bacterial enzymes and the drug is released.

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to various risks, and Prometheus
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
5. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
6. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
7. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
8. Syngenta Licenses Chromatin Gene Stacking Technology
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... to present at 2008 BIO CEO & Investor conference at ... New York on Tuesday, February 12 at 1:15 PM (Eastern), ... -- James A. Bianco, M.D., President and CEO of Cell,Therapeutics, ... overview of,the Company,s sales and marketing strategy intended to grow ...
... eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), ... and interpretation services including,expert consultation and a ... capture and electronic patient reported outcomes,solutions), announced ... fourth quarter,results for the period ended December ...
... CHICAGO, Feb. 11 Advanced Life Sciences,Holdings, Inc. ... in the,discovery, development and commercialization of novel drugs ... diseases today,announced that it will host a conference ... and full-year financial results on Tuesday,February 19 at ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 2Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 3Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 4Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 5eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 3
(Date:8/19/2014)... German . , , ... of plants can switch off individual genes and study ... Planck Institute for Plant Breeding Research in Cologne and ... different approach. They identify small molecules that block specific ... prevent the downstream reactions. In their search for these ...
(Date:8/19/2014)... young have bigger brains than counterparts that don,t care ... study. , Stickleback fish are well known in the ... the species, rather than the female, cares for offspring. ... researchers wanted to find out if the difference in ... , In the study, published recently in Ecology ...
(Date:8/18/2014)... Ariz. Half of the Earth,s land mass is ... yet they are being transformed at an alarming rate. ... in and taking over, leading to a loss of ... ability of ecosystems to produce food specifically meat. ... Life Sciences led an investigation that quantified this loss ...
Breaking Biology News(10 mins):Researchers block plant hormone 2Researchers block plant hormone 3Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3
... N.Y. Proteins are critically important to life and the ... in nature, and there is much we still don,t know ... the stability of enzymes, a particular type of protein that ... natural environment in the cell or body, enzymes can quickly ...
... that nanoparticles, which are now present in everything from ... irreparably damaging effects on soil systems and the environment. ... every year, including silver nanoparticles which are popular as ... Department of Biology. "We started to wonder what the ...
... (April 6, 2011) -- A new drug delivery device ... Peter Rentzepis promises to unlock the potential of photosensitive ... as well. Photosensitive chemicals are molecules that ... These radicals are very active chemically, and can rip ...
Cached Biology News:Nano fit-ness: Helping enzymes stay active and keep in shape 2Common nanoparticles found to be highly toxic to Arctic ecosystem 2New device promises safer way to deliver powerful drugs 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
... Immunogen: Peptide corresponding ... human, mouse, and rat phospho-FAK (Ser843) ... NM_153831 Quality ... Molecular Weight: ...
Biology Products: